Pages that link to "Q53810482"
Jump to navigation
Jump to search
The following pages link to Plasma AR and abiraterone-resistant prostate cancer. (Q53810482):
Displaying 50 items.
- Galeterone for the treatment of advanced prostate cancer: the evidence to date (Q26739887) (← links)
- Advances in genetics: widening our understanding of prostate cancer (Q26740628) (← links)
- In touch with your feminine side: how oestrogen metabolism impacts prostate cancer (Q26748579) (← links)
- Resistance to Novel Antiandrogen Therapies in Metastatic Castration-Resistant Prostate Cancer (Q26751237) (← links)
- Clonal origin and spread of metastatic prostate cancer (Q26752873) (← links)
- Novel Insights into Molecular Indicators of Response and Resistance to Modern Androgen-Axis Therapies in Prostate Cancer (Q28067556) (← links)
- Truncation and constitutive activation of the androgen receptor by diverse genomic rearrangements in prostate cancer. (Q30831010) (← links)
- Lessons from tissue compartment-specific analysis of androgen receptor alterations in prostate cancer (Q36004694) (← links)
- Emerging concepts in liquid biopsies (Q36337259) (← links)
- Androgen Receptor-Dependent and -Independent Mechanisms Involved in Prostate Cancer Therapy Resistance. (Q36398998) (← links)
- Functional analysis of androgen receptor mutations that confer anti-androgen resistance identified in circulating cell-free DNA from prostate cancer patients (Q36508759) (← links)
- Personalized prostate cancer care: from screening to treatment (Q37113160) (← links)
- Precision medicine for advanced prostate cancer (Q37114034) (← links)
- Evaluating Cancer of the Central Nervous System Through Next-Generation Sequencing of Cerebrospinal Fluid (Q37168845) (← links)
- Excerpts from the 1st international NTNU symposium on current and future clinical biomarkers of cancer: innovation and implementation, June 16th and 17th 2016, Trondheim, Norway (Q37349280) (← links)
- Castration-Resistant Prostate Cancer Tissue Acquisition From Bone Metastases for Molecular Analyses (Q37462283) (← links)
- Targeting the N-Terminal Domain of the Androgen Receptor: A New Approach for the Treatment of Advanced Prostate Cancer. (Q37496652) (← links)
- Androgen receptor-dependent and -independent mechanisms driving prostate cancer progression: Opportunities for therapeutic targeting from multiple angles (Q37709535) (← links)
- Detection fidelity of AR mutations in plasma derived cell-free DNA (Q37716596) (← links)
- Androgen receptor mutations in patients with castration-resistant prostate cancer treated with apalutamide (Q38375252) (← links)
- Allosteric alterations in the androgen receptor and activity in prostate cancer. (Q38625010) (← links)
- Prognostic and predictive biomarkers in prostate cancer: latest evidence and clinical implications (Q38644658) (← links)
- Prospects of estrogen receptor β activation in the treatment of castration-resistant prostate cancer (Q38708804) (← links)
- High levels of the AR-V7 Splice Variant and Co-Amplification of the Golgi Protein Coding YIPF6 in AR Amplified Prostate Cancer Bone Metastases (Q38718521) (← links)
- Inhibition of AKR1C3 Activation Overcomes Resistance to Abiraterone in Advanced Prostate Cancer (Q38735379) (← links)
- Novel mechanism-based therapeutics for androgen axis blockade in castration-resistant prostate cancer (Q38775459) (← links)
- Targeting persistent androgen receptor signaling in castration-resistant prostate cancer (Q38797560) (← links)
- Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: a multi-institution correlative biomarker study (Q38804089) (← links)
- Circulating Cell-Free DNA to Guide Prostate Cancer Treatment with PARP Inhibition. (Q38815964) (← links)
- Long-term clinical impact of PSA surge in castration-resistant prostate cancer patients treated with abiraterone. (Q38827364) (← links)
- Selective Glucocorticoid Receptor Modulators (SGRMs) Delay Castrate-Resistant Prostate Cancer Growth. (Q38827723) (← links)
- Androgen receptor variant-driven prostate cancer: clinical implications and therapeutic targeting (Q38835693) (← links)
- Drug discovery in advanced prostate cancer: translating biology into therapy (Q38839110) (← links)
- Liquid biopsy: ready to guide therapy in advanced prostate cancer? (Q38840458) (← links)
- A Pilot Study of Clinical Targeted Next Generation Sequencing for Prostate Cancer: Consequences for Treatment and Genetic Counseling (Q38850529) (← links)
- Analytic Validation of RNA In Situ Hybridization (RISH) for AR and AR-V7 Expression in Human Prostate Cancer (Q38868832) (← links)
- The Role of Next-Generation Sequencing in Castration-Resistant Prostate Cancer Treatment (Q38982680) (← links)
- Cell-free and circulating tumor cell-based biomarkers in men with metastatic prostate cancer: Tools for real-time precision medicine? (Q38988317) (← links)
- New Biomarkers for Selecting the Best Therapy Regimens in Metastatic Castration-Resistant Prostate Cancer (Q38994718) (← links)
- Characterization of an Abiraterone Ultraresponsive Phenotype in Castration-Resistant Prostate Cancer Patient-Derived Xenografts (Q39085996) (← links)
- Liquid biopsies come of age: towards implementation of circulating tumour DNA. (Q39149201) (← links)
- A population genetics perspective on the determinants of intra-tumor heterogeneity (Q39169154) (← links)
- Navigating the evolving therapeutic landscape in advanced prostate cancer (Q39173425) (← links)
- Using molecular diagnostic testing to personalize the treatment of patients with gastrointestinal stromal tumors. (Q39186932) (← links)
- Emerging Variants of Castration-Resistant Prostate Cancer (Q39210257) (← links)
- Extracellular vesicles for liquid biopsy in prostate cancer: where are we and where are we headed? (Q39218490) (← links)
- Recent advances in circulating tumor cells and cell-free DNA in metastatic prostate cancer: a review (Q39454057) (← links)
- Circulating AR copy number and outcome to enzalutamide in docetaxel-treated metastatic castration-resistant prostate cancer. (Q40374954) (← links)
- Whole-genome plasma sequencing reveals focal amplifications as a driving force in metastatic prostate cancer. (Q41868457) (← links)
- Acquiring evidence for precision prostate cancer care. (Q42290401) (← links)